Logo

ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022

Share this

ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022

Shots:

 

  • The P-III (BRIGHTE) study evaluating fostemsavir + OBT in 371 heavily-experienced adults with multidrug-resistant HIV-1 inf. at 113 sites across 22 countries
  • The results showed that patients treated with fostemsavir-based regimens experienced durable virologic responses for 5yrs. In the randomized cohort, 45% of patients achieved virologic suppression, 78% had a change in CD4+ cell count from <200 to ≥200 cells/mm3, and 67% had a change from <20 to ≥200 cells/mm, CD4+/CD8+ ratio also increased steadily from baseline. The safety profile was consistent with prior findings across both cohorts with no new trends in the safety data
  • Additionally, 95% experienced 1 AE; 45% in SAE & 4 patients discontinued treatment due to AE @96wk. & 240wk.

Ref: ViiV Healthcare | Image: ViiV Healthcare

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions